US4772552A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells
Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1984-04-23
•
Granted: 1988-09-20
•
Expires: 2004-04-23
Abstract
Abstract Monoclonal antibody which lyses human natural killer (NK) cells in vitro in the presence of complement and which cells having a molecular weight of about 200-220 KD, as determined by SDS-PAGE electrophoresis on a 10% polyacrylamide gel.
Inventors
- 👤 Thierry Hercend
- 👤 Jerome Ritz
- 👤 Stuart F. Schlossman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 21:26
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; A; A61; A61P; A61P37/00; A61P37/02; A61P37/06; A61K; A61K38/00; Y; Y10; Y10S; Y10S436/00; Y10S436/821; Y10S530/00; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
49 words
A monoclonal antibody which lyses human natural killer cells in vitro in the presence of complement, said antibody recognizing an antigenic determinant on the surface of human natural killer cells having a molecular weight of about 200-220 KD as determined by SDS-PAGE electrophoresis on a 10% polyacrylamide slab gel.
Claim 2
Dependent Claim
49 words
A monoclonal antibody which lyses human natural killer cells in vitro in the presence of complement, said antibody recognizing an antigenic determinant on the surface of human natural killer cells having a molecular weight of about 200-220 KD as determined by SDS-PAGE electrophoresis on a 10% polyacrylamide slab gel.
Claim 3
Dependent Claim
29 words
The antibody of claim 1, said antibody being unreactive with non-natural killer human granulocytes, non-NK human monocytes, human red blood cells, human thymocytes, and non-natural killer human T3 lymphcytes.
Claim 4
Dependent Claim
14 words
The antibody of claim 1, said antibody being of the IgM or IgG2 isotype.
Claim 5
Dependent Claim
10 words
The antibody of claim 1, coupled to a cytotoxic agent.
Claim 6
Dependent Claim
10 words
The antibody of claim 1, labeled with a detectable label.
Claim 7
Dependent Claim
9 words
The antibody of claim 5, said antibody being radiolabeled.
Claim 8
Dependent Claim
10 words
The antibody of claim 5, said antibody being fluorescently labeled.
Claim 9
Dependent Claim
10 words
The monoclonal antibody produced by the hybridoma cell ATCC HB8564.
Claim 10
Dependent Claim
10 words
The monoclonal antibody produced by the hybridoma cell ATCC HB8564.
Claim 11
Dependent Claim
11 words
A hybridoma cell which produces the monoclonal antibody of claim 4.
Claim 12
Dependent Claim
6 words
The hybridoma cell line ATCC HB8564.
Claim 13
Dependent Claim
6 words
The hybridoma cell line ATCC HB8564.
Claim 14
Dependent Claim
68 words
A method of detecting the presence of natural killer or natural-killer-like cells in a human patient comprising contacting a cell-containing clinical sample from said patient with the antibody of claim 1 for a time and under conditions sufficient to form immune complexes between said antibody and said natural killer or natural-killer-like cells in said sample, and detecting immune complexes as an indication of the presence of said cells.
Claim 15
Dependent Claim
44 words
A method of lysing natural killer or natural-killer-like cells in a clinical sample comprising incubating said sample with the antibody of claim 1 in the presence of complement for a time and under conditions sufficient to cause lysis of said cells in said sample.
Claim 16
Dependent Claim
42 words
A method of lysing natural killer cells or natural-killer-like cells in a clinical sample comprising contacting said sample with the cytotoxic agent-coupled antibody of claim 4 for a time and under conditions sufficient to cause lysis of said cells in said sample.
Claim 17
Dependent Claim
28 words
The method of claim 12 or claim 13 wherein said clinical sample is a bone marrow sample, and, following said lysing, said sample is reinfused into a patient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-20 | 1992-03-21 | 1992-09-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-20 | 1996-03-21 | 1996-09-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-20 | 2000-03-21 | 2000-09-20 | $7700.00 | Window Closed / Lapsed |